article thumbnail

Innovative solutions to the drug pricing crisis: the pharmaphorum podcast

pharmaphorum

They discuss out of control drug pricing, especially in the United States, that has led to nonadherence and care rationing. Tune in to learn how at the intersection of patient empowerment and digital health, lies the potential to reduce the impact of high drug prices, if not to mitigate it entirely.

article thumbnail

PBM Industry Update: Trends, Challenges, and What's Ahead (NEW Live Video Webinar)

Drug Channels

Or, download this spreadsheet and email your registrants information to dcisupport@hmpglobal.com. We recommend that every registrant download the Zoom client software/app. This event is part of The Drug Channels 2025 Video Webinar Series. Emerging controversies, challenges, and threats to watch in the industry And much more!

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

NOW AVAILABLE: The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) HMP Global’s Drug Channels Institute releases ‘2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system.

article thumbnail

NOW AVAILABLE: The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Analyzes Impact of Inflation Reduction Act on U.S.

article thumbnail

The Top 15 U.S. Pharmacies of 2023: Market Shares and Revenues at the Biggest Chains and PBMs

Drug Channels

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. For a sneak peek at the complete report, click here to download our free report overview (including key industry trends, the table of contents, and a list of exhibits). to 1:30 p.m.

article thumbnail

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021

Drug Channels

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 The difference between list prices and discounted 340B purchases also grew, to $52.3 d/b/a Drug Channels Institute. billion (+$2.6

article thumbnail

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021 (rerun)

Drug Channels

Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 Every 340B covered entity type experienced double-digit growth, despite drug prices that grew more slowly than overall inflation.